Skip to main content

Preoperative Conformal Radiotherapy Concurrently with Paclitaxel/Carboplatin in Gastric Cancer

مؤلف البحث
Shimaa Ahmed1, Mayada Fawzy2, Khalid Rezk3*, Wessam Elshrif4, Mohamed Alaa5,
Mohamed M. H. Abd Ellah6
المشارك في البحث
قسم البحث
سنة البحث
2018
مجلة البحث
Journal of Cancer Therapy
الناشر
NULL
عدد البحث
Vol. 9
تصنيف البحث
1
صفحات البحث
pp. 503-515
موقع البحث
NULL
ملخص البحث

Background and objectives: Surgery is the primary therapy for localized gastric
cancer, but even with the best results only 40% 5-year survival can be
achieved with the use of postoperative adjuvant chemoradiotherapy. Preoperative
therapy might help increase the R0 resection rate, which is an independent
predictor of 5-year OS. Our study hypothesized that the concurrent
combination of carboplatin-paclitaxel with radiation therapy would result in a
pathological CR rate, which will be in turn associated with OAS and DFS benefits.
Patients and methods: prospective phase II study included 32 patients
with locally advanced gastric adenocarcinoma including gastroesophageal
junction who received a combination of neoadjuvant conformal radiotherapy
concurrently with carboplatin-paclitaxel followed by surgery. Results: Pathological
CR and R0 resection rates were 18.8% and 75% respectively. With a
median follow up of 24 months, 2 years disease-free survival was 28.1% and
overall survival was 51.3%. The regimen was tolerated with neither grade 4
toxicities nor deaths. Conclusion: Neoadjuvant radiotherapy concomitant
with carboplatin-paclitaxel chemotherapy is a well-tolerated approach for patients
with locally advanced gastric adenocarcinoma resulting in significant
pathological CR and R0 resection margins as reflected by the good DFS and
OS.